New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNE;CAT;HES;BBY;KERX;FURX;JOSB;ROP;MW;RPRX;BBBY From The Last 14 Days
Check below for free stories on SNE;CAT;HES;BBY;KERX;FURX;JOSB;ROP;MW;RPRX;BBBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
September 4, 2014
07:36 EDTRPRXRepros Therapeutics weakness a buying opportunity, says Brean Capital
Brean Capital said the recent weakness in Repros Therapeutics is a buying opportunity. The firm said concerns over the upcoming FDA meeting are overblown and shares were substantially oversold in response to negative commentary yesterday. Shares of Repros Therapeutics remain Buy rated with a $41 price target.
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use